PRESS INFORMATION BUREAU पत्र सूचना कार्यालय GOVERNMENT OF INDIA भारत सरकार

Financial Express, Delhi Saturday 7th June 2014, Page: 4 Width: 6.04 cms, Height: 6.70 cms, a4, Ref: pmin.2014-06-07.34.37

Strides gets US FDA nod to market skin disease drug

Strides Arcolab has received regulatory approval to market a skin disease drug in the US. The US Food and Drug Administration (FDA) has allowed the company to sell Methoxsalen capsules of 10 mg strength, Bangalore-based Strides Arcolab said in a statement. The US market for generic Methoxsalen capsules is pegged at about \$13.6 million, with no generic player, the company said, citing IMS data. "The product will be manufactured at the company's Food and Drug Administrationapproved oral dosage facility in Bangalore and marketed directly by Strides in the US," the company said.

Regulatory